For a patient with type 2 diabetes who wishes to avoid weight gain, what therapy adjustment is recommended?

For a patient with type 2 diabetes who wishes to avoid weight gain, adding a GLP-1 receptor agonist to the treatment regimen is recommended. GLP-1 receptor agonists, such as liraglutide and semaglutide, are known for their ability to promote weight loss while effectively controlling blood glucose levels. These medications work by mimicking an incretin hormone that enhances insulin secretion in response to meals, suppresses glucagon release, and promotes satiety, ultimately leading to reduced caloric intake and weight loss.

This makes GLP-1 receptor agonists an ideal choice for patients concerned about weight gain, as they are associated with either weight neutrality or weight loss, unlike some other diabetes medications that often lead to weight gain. By incorporating a GLP-1 receptor agonist, healthcare providers can support better overall health outcomes for patients managing type 2 diabetes, particularly those who are already struggling with obesity or weight management.

In contrast, increasing the metformin dosage typically has a neutral effect on weight, and while metformin is effective in managing glucose levels, it does not actively promote weight loss to the extent of GLP-1 receptor agonists. Starting insulin therapy often leads to weight gain in many patients, as insulin